SEC Comment Letter for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) (CIK 0001187953) (CELZ) — Jan 19, 2018
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) (CIK 0001187953)
Date: Jan. 19, 2018 · CIK: 0001187953 · Accession: 0000000000-18-002014
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-53500
Letter
January 19, 2018 Timothy Warbington Chief Executive Officer Creative Medical Technology Holdings, Inc. 2017 W Peoria Avenue Phoenix, AZ 85029 Re:Creative Medical Technology Holdings, Inc. Preliminary Information Statement on Schedule 14C Filed January 12, 2018 File No. 000-53500 Dear Mr. Warbington: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Information Statement on Schedule 14C filed January 12, 2018 Amendment to the Articles of Incorporation to Increase Authorized Shares of Common Stock from 600,000,000 to 3,000,000,000 Outstanding Shares and Purpose of the Amendment, page 3 1.We note your disclosure that you have entered into a series of financing transactions that require you to maintain a reserve of shares for conversions of outstanding debt which are at multiples based on your issued and outstanding shares of common stock. Please expand your disclosure to provide (i) the amount of the newly authorized shares of common stock that will be issued as a result of conversions of your outstanding debt, (ii) the amount of newly authorized shares of common stock that are required to be held in reserve under your financing agreements and (iii) the general effect of the issuance of the shares of common stock as a result of conversions of your outstanding debt upon the rights of existing security holders. Refer to Item 11(c) and (d) and Note A of Schedule 14A.
FirstName LastNameTimothy Warbington Comapany NameCreative Medical Technology Holdings, Inc. June 16, 2017 Page 2 FirstName LastName Timothy Warbington Creative Medical Technology Holdings, Inc. January 19, 2018 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 or Erin Jaskot at 202-551-3442 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ronald N. Vance - Vance, Higley &Associates, P.C.
Show Raw Text
January 19, 2018
Timothy Warbington
Chief Executive Officer
Creative Medical Technology Holdings, Inc.
2017 W Peoria Avenue
Phoenix, AZ 85029
Re:Creative Medical Technology Holdings, Inc.
Preliminary Information Statement on Schedule 14C
Filed January 12, 2018
File No. 000-53500
Dear Mr. Warbington:
We have reviewed your filing and have the following comment.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Information Statement on Schedule 14C filed January 12, 2018
Amendment to the Articles of Incorporation to Increase Authorized Shares of Common Stock
from 600,000,000 to 3,000,000,000
Outstanding Shares and Purpose of the Amendment, page 3
1.We note your disclosure that you have entered into a series of financing transactions that
require you to maintain a reserve of shares for conversions of outstanding debt which are
at multiples based on your issued and outstanding shares of common stock. Please
expand your disclosure to provide (i) the amount of the newly authorized shares of
common stock that will be issued as a result of conversions of your outstanding debt, (ii)
the amount of newly authorized shares of common stock that are required to be held in
reserve under your financing agreements and (iii) the general effect of the issuance of the
shares of common stock as a result of conversions of your outstanding debt upon the
rights of existing security holders. Refer to Item 11(c) and (d) and Note A of Schedule
14A.
FirstName LastNameTimothy Warbington
Comapany NameCreative Medical Technology Holdings, Inc.
June 16, 2017 Page 2
FirstName LastName
Timothy Warbington
Creative Medical Technology Holdings, Inc.
January 19, 2018
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Irene Paik at 202-551-6553 or Erin Jaskot at 202-551-3442 with any
questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Ronald N. Vance - Vance, Higley &Associates, P.C.